Shangqin Guo, Ph.D., a scientist at Yale University, is the recipient of the 2014 STEM CELLS Young Investigator Award. The award is presented to a young researcher who serves as principal author of a significant study published in the journal over the past year.
You are here
Press Releases from AlphaMed Press
Embargo Policy: Articles for STEM CELLS and STEM CELLS Translational Medicine are embargoed for release until 9 a.m. Eastern U.S. time on the day the article is posted online. This policy applies to members of the media, authors, institutions' public information officers, and the public. Authors may not discuss their work with the media until 1 week before the mailing date or 1 week before online posting of the article, whichever is earlier, and must ensure that the media representatives agree to abide by the embargo policy. STEM CELLS Translational Medicine may refuse to publish a manuscript, despite acceptance for publication, if it has been prematurely released to the press.
With more soldiers returning from combat suffering devastating injuries, doctors are turning to a reconstructive surgery that uses tissue transplantation along with immuno-suppression therapy. This approach has had encouraging results; however, rejection of transplanted tissue from an unmatched donor remains a critical complication. A new study found in the latest issue of STEM CELLS Translational Medicine reports that researchers may have found a way around that.
Half of all traumatic injuries to the face result in a loss of teeth and the surrounding tissue and bone that once supported them, which in turn makes these types of injuries very debilitating and difficult to treat. But in a new study published in the latest issue of STEM CELLS Translational Medicine, doctors at the University of Michigan School of Dentistry (UMSoD), Ann Arbor, have found a new way to regenerate a patient’s jawbone through the use of stem cells.
The procedure, done under local anesthesia, significantly speeds up the healing time relative to that of traditional bone grafting while allowing a patient to experience only a minimal amount of pain.
A new way to produce engineered skin not only appears to overcome several pitfalls of current skin grafting technologies, it also speeds up the healing process, reduces scarring and produces hair. The method, outlined in the October issue of STEM CELLS Translational Medicine, could represent a breakthrough for treating deep skin injuries that result from severe burns and chronic wounds.
In a recent study published in STEM CELLS Translational Medicine, scientists have found what they believe might be a better way to regrow bone tissue using magnetic nanoparticles coated with targeting proteins that stimulate stem cells to regenerate the bone. They also were able to deliver the cells directly to the injured area, remotely control the nanoparticles to generate mechanical forces and maintain the regeneration process through staged releases of a protein growth factor. These findings might someday have significant impact for anyone suffering from a major bone trauma, disease or defect.
A study published in STEM CELLS on August 30, 2014, details a new, simple, and highly efficient way to convert cells taken from an adult’s skin into stem cells that have the potential to differentiate into white blood cells.
Stem cells are the keystone of regenerative medicine due to their ability to be coaxed into becoming nearly any cell in the body. Induced pluripotent stem cells (iPSCs) are of particular interest because they can be generated directly from adult cells and thus many of the controversies associated with embryonic stem cells are avoided.
Human induced pluripotent stem cells (hiPSCs) have great potential in the field of regenerative medicine because they can be coaxed to turn into specific cells; however, the new cells don’t always act as anticipated. They sometimes mutate, develop into tumors or produce other negative side effects. But in a new study recently published in STEM CELLS Translational Medicine, researchers appear to have found a way around this, simply by removing the material used to reprogram the stem cell after they have differentiated into the desired cells.
The study, by Ken Igawa, M.D., Ph.D., and his colleagues at Tokyo Medical and Dental University along with a team from Osaka University, could have significant implications both in the clinic and in the lab.
Medication and minimally invasive surgery to implant a sling can provide relief for millions of people who suffer from stress urinary incontinence (SUI), but not everyone responds to these therapeutic methods. A new study in the current STEM CELLS Translational Medicine tests the safety and effectiveness of stem cells as an alternative SUI treatment.
SUI results when the pelvic floor muscles, which support the bladder and urethra, weaken to the point that the muscles are not able to prevent urine from flowing when pressure is placed on the abdomen, such as when the person laughs or coughs. It occurs most often in women, due to childbirth and pregnancy.
A new study released today in STEM CELLS Translational Medicine suggests a new way to produce endothelial progenitor cells in quantities large enough to be feasible for use in developing new cancer treatments.
Endothelial progenitor cells (EPCs) are rare stem cells that circulate in the blood with the ability to differentiate into the cells that make up the lining of blood vessels. With an intrinsic ability to home to tumors, researchers have focused on them as a way to deliver gene therapy straight to the cancer. However, the challenge has been to collect enough EPCs for this use.
Patients with a particularly stubborn type of breast cancer could potentially benefit by supplementing radiation treatments with a generic, low-cost medication commonly prescribed to treat high cholesterol, according to a new study released today in Stem Cells Translational Medicine.